Indications
Opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid ?- glucosidase [GAA] deficiency).
Composition
- Active substance
- miglustat
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Opfolda
- Active substance
- miglustat
- ATC code
- A16AX06
- Therapeutic area
- Glycogen Storage Disease Type II
- Marketing authorisation holder
- Amicus Therapeutics Europe Limited
- Status
- Authorised
- EU authorisation